Get the Stockscreener App
1.27
9.48%
0.11
After Hours:
1.28
0.01
+0.79%
Clearside Biomedical Inc stock is traded at $1.27, with a volume of 670.76K.
It is up +9.48% in the last 24 hours and up +25.74% over the past month.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
See More
Previous Close:
$1.16
Open:
$1.15
24h Volume:
670.76K
Relative Volume:
2.67
Market Cap:
$86.70M
Revenue:
$8.23M
Net Income/Loss:
$-32.49M
P/E Ratio:
-2.1525
EPS:
-0.59
Net Cash Flow:
$-19.91M
1W Performance:
+5.83%
1M Performance:
+25.74%
6M Performance:
-16.99%
1Y Performance:
+45.99%
1-Day Range:
$1.15
$1.31
1-Week Range:
$1.09
$1.31
52-Week Range:
$0.6501
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
Name
Clearside Biomedical Inc
Sector
Industry
Phone
678-270-3631
Address
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-21 | Resumed | Wedbush | Outperform |
| Jul-29-21 | Initiated | H.C. Wainwright | Buy |
| May-13-20 | Initiated | ROTH Capital | Buy |
| Aug-09-19 | Downgrade | Needham | Buy → Hold |
| Nov-05-18 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-05-18 | Downgrade | JP Morgan | Overweight → Underweight |
| Nov-05-18 | Downgrade | Stifel | Buy → Hold |
| Mar-06-18 | Reiterated | Needham | Buy |
| May-25-17 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-17 | Initiated | JP Morgan | Overweight |
| Nov-10-16 | Reiterated | Needham | Buy |
| Oct-24-16 | Reiterated | Stifel | Buy |
View All
Clearside Biomedical Inc Stock (CLSD) Latest News
Wall Street SWOT: Clearside Biomedical stock eyes ODYSSEY trial success - Investing.com
Armistice Capital LLC Has $2.78 Million Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - MarketBeat
CLSD’s Stock Market Journey: A Year of Growth, Decline, and Uncertainty - The InvestChronicle
Financial Health Report: Clearside Biomedical Inc (CLSD)’s Ratios Tell a Tale - The Dwinnex
Can Clearside's ODYSSEY Trial Data Delight Investors? - RTTNews
CLSD’s Stock Market Adventure: 5.13% YTD Growth Amidst Volatility - The InvestChronicle
Nothing is Better Than Clearside Biomedical Inc (CLSD) stock at the moment - SETE News
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Large Increase in Short Interest - MarketBeat
Clearside Biomedical Inc [CLSD] Shares Rise 3.05 % on Thursday - Knox Daily
Was anything positive for Clearside Biomedical Inc (CLSD) stock last session? - US Post News
Clearside Biomedical Inc (CLSD) Stock: Navigating a Year of Volatility - The InvestChronicle
The Attractiveness of Investing In Clearside Biomedical Inc (CLSD) is Growing - Knox Daily
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Average Rating of "Buy" from Brokerages - MarketBeat
International Assets Investment Management LLC Has $26,000 Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Share Price Crosses Below Fifty Day Moving Average of $1.12 - MarketBeat
Market Resilience: Clearside Biomedical Inc (CLSD) Finishes Weak at 0.93, Down -3.40 - The Dwinnex
Analysts review Clearside Biomedical Inc’s rating - Knox Daily
Clearside Slips on Trials - MSN
Clearside Biomedical Inc [CLSD] Investment Guide: What You Need to Know - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Clearside Biomedical Inc (CLSD) - The Dwinnex
Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at HC Wainwright - Defense World
Clearside Biomedical (NASDAQ:CLSD) Receives Buy Rating from HC Wainwright - MarketBeat
Jones Trading maintains stock target, buy rating on Clearside Biomedical By Investing.com - Investing.com Canada
Jones Trading maintains stock target, buy rating on Clearside Biomedical By Investing.com - Investing.com UK
Clearside Slips on Trials - Baystreet.ca
Clearside Biomedical Announces Completion of Final - GlobeNewswire
Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD - StockTitan
Assenagon Asset Management S.A. Buys Shares of 283,193 Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Brokers Issue Forecasts for Clearside Biomedical, Inc.'s FY2024 Earnings (NASDAQ:CLSD) - MarketBeat
Brokers Issue Forecasts for Clearside Biomedical, Inc.’s FY2024 Earnings (NASDAQ:CLSD) - Defense World
Assenagon Asset Management S.A. Takes $368,000 Position in Clearside Biomedical, Inc. (NASDAQ:CLSD) - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Earns Buy Rating from Analysts at Chardan Capital - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Research Coverage Started at Chardan Capital - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Shares Bought by Vanguard Group Inc. - Defense World
Clearside Biomedical (CLSD) Stock Price, News & Analysis - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) to Post Q3 2024 Earnings of ($0.13) Per Share, HC Wainwright Forecasts - Defense World
Q3 2024 EPS Estimates for Clearside Biomedical, Inc. (NASDAQ:CLSD) Increased by Analyst - MarketBeat
Oppenheimer gives an Outperform recommendation for Clearside Biomedical Inc (CLSD) - Knox Daily
Clearside Biomedical (NASDAQ:CLSD) Receives “Buy” Rating from HC Wainwright - Defense World
Clearside Biomedical (NASDAQ:CLSD) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 76.8% in July - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Up 76.8% in July - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $4.60 Consensus Price Target from Analysts - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Clearside Biomedical (NASDAQ:CLSD) Earns Buy Rating from Needham & Company LLC - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at Needham & Company LLC - Defense World
CLSD Stock Earnings: Clearside Biomedical Beats EPS, Misses Revenue for Q2 2024 - InvestorPlace
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update - wallstreet:online
Clearside Biomedical Inc Stock (CLSD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):